These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31569304)

  • 21. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606.
    Mancini M; Brusa G; Zuffa E; Corrado P; Martinelli G; Grafone T; Barbieri E; Santucci MA
    Leuk Res; 2007 Jul; 31(7):979-87. PubMed ID: 17129604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
    Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
    Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-survivin effect of the small molecule inhibitor YM155 in RCC cells is mediated by time-dependent inhibition of the NF-κB pathway.
    Sim MY; Yuen JSP; Go ML
    Sci Rep; 2018 Jul; 8(1):10289. PubMed ID: 29980758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Sonnichsen D
    Int J Cancer; 2012 Aug; 131(3):E304-11. PubMed ID: 22065400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.
    Kim WG; Guigon CJ; Fozzatti L; Park JW; Lu C; Willingham MC; Cheng SY
    Clin Cancer Res; 2012 Mar; 18(5):1281-90. PubMed ID: 22271876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
    Ozanne J; Prescott AR; Clark K
    Biochem J; 2015 Jan; 465(2):271-9. PubMed ID: 25351958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutrophil FcγRIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases.
    Nishi H; Furuhashi K; Cullere X; Saggu G; Miller MJ; Chen Y; Rosetti F; Hamilton SL; Yang L; Pittman SP; Liao J; Herter JM; Berry JC; DeAngelo DJ; Zhu C; Tsokos GC; Mayadas TN
    J Clin Invest; 2017 Oct; 127(10):3810-3826. PubMed ID: 28891817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
    Homsi J; Cubitt CL; Zhang S; Munster PN; Yu H; Sullivan DM; Jove R; Messina JL; Daud AI
    Melanoma Res; 2009 Jun; 19(3):167-75. PubMed ID: 19434004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
    Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
    Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.
    MacDonald RJ; Bunaciu RP; Ip V; Dai D; Tran D; Varner JD; Yen A
    Leuk Lymphoma; 2018 Dec; 59(12):2941-2951. PubMed ID: 29569971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
    Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bosutinib Stimulates Macrophage Survival, Phagocytosis, and Intracellular Killing of Bacteria.
    da Silva RAG; Stocks CJ; Hu G; Kline KA; Chen J
    ACS Infect Dis; 2024 May; 10(5):1725-1738. PubMed ID: 38602352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.
    Redaelli S; Boschelli F; Perini P; Pirola A; Viltadi M; Gambacorti-Passerini C
    Leukemia; 2010 Jun; 24(6):1223-7. PubMed ID: 20445575
    [No Abstract]   [Full Text] [Related]  

  • 34. Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.
    Tarpley M; Abdissa TT; Johnson GL; Scott JE
    Anticancer Res; 2014 Apr; 34(4):1629-35. PubMed ID: 24692691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
    Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
    Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
    Hill BG; Kota VK; Khoury HJ
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
    Golas JM; Lucas J; Etienne C; Golas J; Discafani C; Sridharan L; Boghaert E; Arndt K; Ye F; Boschelli DH; Li F; Titsch C; Huselton C; Chaudhary I; Boschelli F
    Cancer Res; 2005 Jun; 65(12):5358-64. PubMed ID: 15958584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-κB activation.
    Bai C; Yang X; Zou K; He H; Wang J; Qin H; Yu X; Liu C; Zheng J; Cheng F; Chen J
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):573-84. PubMed ID: 26935715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth.
    Tauer JT; Hofbauer LC; Jung R; Erben RG; Suttorp M
    Med Sci Monit Basic Res; 2013 Nov; 19():274-8. PubMed ID: 24185529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
    Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
    Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.